greeksoup/ stock research

Utah Medical Products Inc.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 29 January 2026: press release. Guidance figures: 1 raised. The quarter’s numbers.

Key takeaways

  • Full-year sales fell 5.8%: Full-year sales fell 5.8% to $38.5 million, a $2.4 million decline driven mainly by PendoTECH OEM sales, which fell $2.3 million. Source
  • Gross margin near prior-year levels: Gross margin was 57.1% for 2025 against 59.0% in 2024, and 58.2% in 4Q 2025 against 58.1%. Operating margin for 2025 was 29.6% against 33.2%. Source
  • Operating income fell 16.1%: Operating income fell 16.1% for the year to $11,402 and 16.7% in the fourth quarter to $2,442. Source
  • Outside-US sales down 9.7% in USD: Outside-US sales fell 9.7% in USD to $15,758. In constant currency they were 12.0% lower, with stronger euro and pound adding $397 to reported sales. Source
  • Outside-US Filshie sales fell $1,181: Outside-US Filshie device sales, shipped from Ireland or the UK, fell $1,181 across direct and distributor channels in 2025. Source
  • Product liability legal expenses fell: U.S. product liability legal expenses fell to $1,355 from $2,139. Litigation expense was $783 lower for the year but $46 higher in 4Q 2025. Source
  • 2026 OEM and China sales zero: Management expects 2026 sales of PendoTECH OEM products and China blood pressure kits to be zero, against about $2.5 million in 2025. Source
  • Plan to replace lost sales: Management plans to offset those losses through new products, including biopharma sales, plus modest organic growth and Filshie improvement. Source

“Nevertheless the Company retained excellent profit margins, and increased its year-ending cash balances to $85.8 million despite paying $4.0 million in dividends to stockholders.”

Utah Medical Products Inc., press release

Guidance

AreaPeriodFigureAgainst last quarter
Quarterly dividend per share Sourcefrom January 2026 payment$0.310 per shareRaised from $0.305
FX rates in financial projections Source2026same exchange rates as 4Q 2025

What changed from last quarter

  • Guidance raised: Quarterly dividend raised to $0.310 per share from the January 2026 payment. Source
  • New guidance: 2026 sales of PendoTECH OEM products and China kits set at zero. Source
  • New: New product sales, including other biopharma customers, planned to replace lost OEM and China sales. Source

Full-year and fourth-quarter results

  • Full-year sales fell 5.8%: Full-year sales fell 5.8% to $38.5 million, a $2.4 million decline driven mainly by PendoTECH OEM sales, which fell $2.3 million. Source
  • Fourth-quarter sales down 1.2%: Fourth-quarter sales were $9,044, down $113 (1.2%). Operating income fell 16.7% to $2,442 and diluted EPS fell 6.3% to $0.802. Source
  • Gross margin near prior-year levels: Gross margin was 57.1% for 2025 against 59.0% in 2024, and 58.2% in 4Q 2025 against 58.1%. Operating margin for 2025 was 29.6% against 33.2%. Source
  • Operating income fell 16.1%: Operating income fell 16.1% for the year to $11,402 and 16.7% in the fourth quarter to $2,442. Source
  • Diluted EPS fell less than income: Net income fell 18.7% to $11,286. Diluted EPS fell 12.1% to $3.483, a smaller drop than the 16.1% fall in operating income, which the company attributed to fewer diluted shares. Source

Sales by region and channel

  • Domestic U.S. sales down 2.9%: Domestic U.S. sales fell 2.9% for the year. Lower PendoTECH sales of $1,866 were offset by $1,183 of higher other domestic sales. Source
  • Outside-US sales down 9.7% in USD: Outside-US sales fell 9.7% in USD to $15,758. In constant currency they were 12.0% lower, with stronger euro and pound adding $397 to reported sales. Source
  • Fourth-quarter U.S. down, OUS up: Fourth-quarter U.S. sales fell 4.9% while OUS sales rose 4.9% in USD terms. Constant-currency OUS sales were up 0.5%. Source
  • Distributor orders shifted to Ireland: U.S.-shipped distributor sales fell 18% in 4Q 2025, as some orders were accepted in Ireland to help balance production capacity. Source

“Despite lower sales, profit margins in 4Q and year 2025 held up well compared to 4Q and year 2024, for reasons described later in this report”

Utah Medical Products Inc., press release

Filshie and other device sales

  • Domestic Filshie sales rose: Domestic Filshie device sales rose $436 (+10.8%) for the year, and direct Filshie sales rose 21.6% in the fourth quarter. Source
  • Outside-US Filshie sales fell $1,181: Outside-US Filshie device sales, shipped from Ireland or the UK, fell $1,181 across direct and distributor channels in 2025. Source
  • Other domestic devices rose: Other domestic direct device sales rose $872 (+5.9%), led by a 16% increase in NICU device sales. Source
  • PendoTECH biopharma OEM sales fell: Biopharma OEM sales to PendoTECH fell $2,295 (85%) as expected, with $1,866 in U.S. OEM sales and $429 in Ireland OUS sales. Source

Costs, margins and operating expenses

  • Cost-of-living and raw material inflation: Gross margin declined on employee cost-of-living adjustments and raw-material inflation. In 4Q 2025 the margin held at the 2024 level, partly because of absent low-margin China distributor sales. Source
  • Operating income fell $2,192: Operating income fell $2,192: gross profit was $2,142 lower and operating expenses $50 higher. Source
  • FX added to operating expenses: A stronger euro and pound added $41 to fourth-quarter operating expenses and $109 for the year. Source
  • Operating expenses held near prior level: Total operating expenses were $10,599 for the year, 27.5% of sales, against $10,549 (25.8%). Fourth-quarter operating expenses were $2,822 (31.2% of sales). Source

Litigation and one-time items

  • Product liability legal expenses fell: U.S. product liability legal expenses fell to $1,355 from $2,139. Litigation expense was $783 lower for the year but $46 higher in 4Q 2025. Source
  • Most courts dismissed lawsuits: Fourteen of nineteen courts had dismissed the lawsuits as of January 2026. No case has gone to trial yet. Source
  • China distributor fees written off: Management recorded a $395 write-off of cancellation fees owed by the China distributor, within G&A expenses. Source
  • Former Australia manager embezzlement loss: A $195 loss of funds embezzled by the former Australia subsidiary manager was recognized in 4Q 2025. Repayment has not been made. Source
  • China order cancelled in 3Q: The China distributor's 2025 blood pressure kit order was cancelled in 3Q 2025, $431 below the amount committed. Source

Plans for 2026

  • 2026 OEM and China sales zero: Management expects 2026 sales of PendoTECH OEM products and China blood pressure kits to be zero, against about $2.5 million in 2025. Source
  • Plan to replace lost sales: Management plans to offset those losses through new products, including biopharma sales, plus modest organic growth and Filshie improvement. Source
  • Projections use 4Q 2025 FX rates: Projections assume 2026 exchange rates equal to 4Q 2025 rates, since the company cannot predict the FX impact. Source

Cash, buybacks and dividends

  • Cash and investments rose $2.8 million: Cash and investments rose $2.8 million to $85.8 million after $4.0 million of dividends and $8.4 million of share repurchases. Source
  • Share buybacks of 148,935 shares: The company bought back 148,935 shares in 2025 at an average $56.10, for $8,355 in total. Source
  • Dividends paid $3,983 in 2025: Dividends paid in 2025 were $3,983 ($1.22 per share), lower in total than 2024 because of fewer shares outstanding. Source
  • No debt at year-end: The company reported no debt at December 31, 2025. Source
  • Non-cash working capital declined: Non-cash working capital fell $210, with inventories down $877 and receivables down $573 on lower sales. Source

Share price and share count

  • Share price down 9.0%: The share price closed the year at $55.96, down 9.0% for 2025. The Dow rose 13.0%, the S&P 500 16.4% and the NASDAQ 20.4%. Source
  • Three consecutive years of share price declines: The company noted this is the first three-year run of share price declines in 27 years. Source
  • Fewer diluted shares outstanding: Diluted shares averaged 3,239,927 for 2025, down from 3,503,165 in 2024. Source

Coming up, as management said on 29 January 2026

  • Annual 10-K filing by March 27: The company said its 2025 Form 10-K will be filed on or before March 27, 2026. Source
  • Four summary judgment rulings pending: Four cases await court decisions on UTMD summary judgment motions. A denied motion would send that case to trial. Source

Figures management reported

FigureReported
Filshie clips sold, unit volume change Source+12%

Risks management discussed

  • Regulatory: Litigation expense could rise significantly if any case goes to trial; no case has gone to trial so far. Source
  • Demand: Management said plans to replace 2026 OEM and China kit sales carry substantial uncertainty. Source
  • External: 2026 projections are built on 4Q 2025 exchange rates, as the company cannot predict the FX impact. Source
  • Operational: Supplier raw material costs kept rising and employee cost-of-living adjustments added to cost pressure on gross margin. Source

Earlier plans management reported on

  • Missed: Management states it did not achieve its beginning-of-year 2025 financial projections. Source
  • Met: Management described the 2025 gross margin decline as expected. Source
  • Not stated: Management plans to offset the expected 2026 loss of OEM and China kit sales, with substantial uncertainty noted. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.